Do you have patients treated with adalimumab? Know the safety profile

Adalimumab, a fully human antibody to tumor necrosis factor (TNF), was first approved by the Food and Drug Administration (FDA) in 2002 for the treatment of rheumatoid arthritis. In 2008, it was approved for treatment of polyarthritis juvenile idiopathic arthritis and has since been approved for other pediatric indications that cross several subspecialties, including dermatology, gastroenterology and ophthalmology. Thus, it is important for a growing number of pediatricians, including those in primary care, to be aware of the safety profile of this widely used biologic medication.
Source: The Journal of Pediatrics - Category: Pediatrics Authors: Tags: The Editors' Perspectives Source Type: research